Seattle Genetics is perhaps one of the lesser known innovators in the scientific world. Under the leadership of Clay Siegall, the company has grown to be a lot more than just a whisper in the wind. Siegall founded Seattle Genetics in 1998. Siegall is a trained scientist and specialized in cancer research. When he founded Seattle genetics, he wanted them to be a leader in innovation as well as research that was described as rigorous and overall a sense of wanting to help others to live a better and more productive life.
Siegall and his team help to develop antibody drug conjugates. This development helped later on to lead to the 2011 approval of their first ADC product named ADCETRIS. It has went on to become approved in more than 60 countries and has helped to put Siegall and Seattle Genetics in the public eye. With his leadership, Seattle Genetics has been able to partner with a number of manufacturers including Genentech, GlaxoSmithCline as well as Pfizer and have generated more than 300 million to date.
Using Seattle Genetics technology through a series of collaborations there are more than 20 ADC’s currently in development. Siegall has also been responsible for a large amount of capital fund raising totaling around 1.2 billion that was secured through a series of public and private fund raising. Before founding Seattle genetics, Clay Siegal was active with a number of companies, in the medical industry. Before he started his career, Siegal received a Ph.D in genetics from George Washington University and a degree in zoology from the University of Maryland.
With Clay Siegall’s leadership and the technological advances that Seattle Genetics are making, it is easy to see how this will lead to there being a lot of advances in the coming years that will hopefully help to conquer a number of the diseases that have been plaguing us all these years.